Hostname: page-component-cb9f654ff-kl2l2 Total loading time: 0 Render date: 2025-09-05T12:32:20.180Z Has data issue: false hasContentIssue false
  • English
  • Français

Synthetic Peptides and Purified Antigens as Vaccines

Published online by Cambridge University Press:  14 October 2009

Fred Brown
Fred Brown
Affiliation:
U.S. Food and Drug Administration
Get access Rights & Permissions [Opens in a new window]

Abstract

Molecular biology and, in particular, knowledge of the immune response at the molecular level provide the research community with the opportunity to design vaccines that will elicit the appropriate responses for many diseases. The critical issue is to identify the immune response that correlates with protection. It is remarkable how well the empirical approach has worked; it is essential, therefore, not to ignore the lessons to be learned from these successes. It is particularly essential that each disease and the immune response that affords protection be studied individually so that the appropriate responses can be induced.

Information

Type
Special Section: Vaccines and Public Health: Assessing Technologies and Public Policies
Information
International Journal of Technology Assessment in Health Care , Volume 10 , Issue 1 , Winter 1994 , pp. 161 - 166
Copyright
Copyright © Cambridge University Press 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

REFERENCES

1.Anderer, F.Versuche zur bestimmung der serologisch terminaten gruppen des tobakmo-saikvirus. Zeitschrift fur Naturforschung Teil B, 1963, 188, 1010–14.CrossRefGoogle Scholar
2.Borras-Cuesta, F., Petit-Carmurdan, A., & Fedan, Y.Engineering of immunogenic pep-tides by co-linear synthesis of determinants recognized by B and T cells. European Journal of Immunology, 1987, 17, 1213–16.CrossRefGoogle Scholar
3.Brown, F.Synthetic viral vaccines. Annual Review of Microbiology. 1984, 38: 221–35.CrossRefGoogle ScholarPubMed
4.Brown, F., Schild, G. C., & Ada, G. L.Recombinant vaccinia viruses as vaccines. Nature, 1986, 319, 549–50.CrossRefGoogle ScholarPubMed
5.Dougan, C., & Tite, J.Livebacterial vaccines for delivering antigens to the mammalian immune system. Seminars in Virology, 1990, 1, 29–37.Google Scholar
6.Francis, M. J., Hastings, G. Z., Syred, A. D., et al. Nonresponsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants. Nature, 1987, 330, 168–70.CrossRefGoogle ScholarPubMed
7.Good, M. F., Maloy, W. L., Lunde, M. N., et al. Construction of synthetic immunogen; use of new T-helper epitope on malaria circumsporozoite protein. Science, 1987, 235, 1059–62.CrossRefGoogle ScholarPubMed
8.Langebeheim, H., Arnon, R., & Sela, M.Antiviral effect on MS2 coliphage obtained with a synthetic antigen. Proceedings of the National Academy of Sciences of the United States of America, 1987, 73, 4636–40.CrossRefGoogle Scholar
9.Leclerc, C., Przewlocki, G., Schutze, M., et al. A synthetic vaccine constructed by copoly-merization of B and T cell determinants. European Journal of Immunology, 1987, 17, 269–73.CrossRefGoogle Scholar
10.Margalit, H., Spouge, J. L., Cornette, J. L., et al. Prediction of immunodominant helper T cell antigenic sites from the primary sequence. Journal of Immunology, 1987, 138, 2213–29.CrossRefGoogle ScholarPubMed
11.Maxam, A. M., & Gilbert, W.A new method for sequencing DNA. Proceedings of the National Academy of Sciences of the United States of America, 1977, 74, 560–65.CrossRefGoogle ScholarPubMed
12.Milich, D. R.Synthetic peptides: Prospects for vaccine development. Seminars in Immunology, 1990, 2, 307–15.Google ScholarPubMed
13.Morein, B., Fossum, C., Lovgren, K., et al. The iscom-a modern approach to vaccines. Seminars in Virology, 1990, 1, 49–55.Google Scholar
14.Muller, S., Plaue, S., Samama, J. P., et al. Antigenic properties and protective capacity of a cyclic peptide correspondingto site A of influenza virus haemagglutin. Vaccine, 1990, 8, 308–14.CrossRefGoogle Scholar
15.Rothbard, J. B., & Taylor, W. R.A sequence pattern common to T cell epitopes. EMBO Journal, 1988, 7, 93–100.CrossRefGoogle ScholarPubMed
16.Sanger, F., Nicklen, S., & Coulson, A. R.DNA sequencing with chain-terminating inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 1977, 74, 5463–67.CrossRefGoogle ScholarPubMed
17.Valenzuela, P., Tekamp-OIson, P., Coit, D., et al. Characterization of hepatitis B antigen particles produced in yeast. In Chanock, R. M., & Lerner, R. A. (eds.), Modern approaches to vaccines, Cold Spring Harbor, NY: 1984, 209–13.Google Scholar